This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chang, P.-Y. Articles by Miyamoto, S. Search for Related Content PubMed PubMed Citation Articles by Chang, P.-Y. Articles by Miyamoto, S.

NFKB1 Is a Direct Target of the TAL1 Oncoprotein in Human T Leukemia Cells

¹ Program in Molecular and Cellular Pharmacology, Department of Pharmacology, University of Wisconsin-Madison, Madison, Wisconsin and ² Department of Cancer Biology and the Cancer Center, University of Massachusetts Medical School, Worcester, Massachusetts

Requests for reprints: Shigeki Miyamoto, Department of Pharmacology, University of Wisconsin, 301 Medical Sciences Center, 1300 University Avenue, Madison, WI 53706. Phone: 608-262-9281; Fax: 608-262-1257; E-mail: smiyamot{at}wisc.edu.

We recently showed that a subset of human T acute lymphoblastic leukemia (T-ALL) cell lines expresses low basal levels of p50, a nuclear factor-B (NF-B)/Rel family member, resulting in their capacity to activate the atypical p65:cRel complex rather than the classic p50:p65 dimer. Here, we show that the transcription factor TAL1 (also known as SCL) binds to the promoter of the NFKB1 gene that encodes p50 and represses its transcription to set up this unique response in T-ALL cells. When TAL1 expression is reduced in CEM T leukemia cells, basal NFKB1 expression is increased, and the levels of p65:cRel complex and transcription of its target gene, such as intercellular adhesion molecule-1 (ICAM-1), are reduced in response to etoposide treatment. Moreover, a significant negative correlation between NFKB1 and TAL1 or LMO1 was found in primary human TAL1/LMO1 double-positive T-ALL samples previously described by Ferrando et al. Thus, TAL1 modulates NFKB1 expression and an NF-B-dependent transcriptional program in a subset of human T-cell leukemia cells. (Cancer Res 2006; 66(12): 6008-13)

This article has been cited by other articles:

				J.-M. Terme, M. Wencker, A. Favre-Bonvin, F. Bex, L. Gazzolo, M. Duc Dodon, and P. Jalinot Cross Talk between Expression of the Human T-Cell Leukemia Virus Type 1 Tax Transactivator and the Oncogenic bHLH Transcription Factor TAL1 J. Virol., August 15, 2008; 82(16): 7913 - 7922. [Abstract] [Full Text] [PDF]